Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease

This article has been updated

Abstract

Profound neuronal dysfunction in the entorhinal cortex contributes to early loss of short-term memory in Alzheimer's disease1,2,3. Here we show broad neuroprotective effects of entorhinal brain-derived neurotrophic factor (BDNF) administration in several animal models of Alzheimer's disease, with extension of therapeutic benefits into the degenerating hippocampus. In amyloid-transgenic mice, BDNF gene delivery, when administered after disease onset, reverses synapse loss, partially normalizes aberrant gene expression, improves cell signaling and restores learning and memory. These outcomes occur independently of effects on amyloid plaque load. In aged rats, BDNF infusion reverses cognitive decline, improves age-related perturbations in gene expression and restores cell signaling. In adult rats and primates, BDNF prevents lesion-induced death of entorhinal cortical neurons. In aged primates, BDNF reverses neuronal atrophy and ameliorates age-related cognitive impairment. Collectively, these findings indicate that BDNF exerts substantial protective effects on crucial neuronal circuitry involved in Alzheimer's disease, acting through amyloid-independent mechanisms. BDNF therapeutic delivery merits exploration as a potential therapy for Alzheimer's disease.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: BDNF effects in APP-transgenic mice.
Figure 2: BDNF effects in aged rats.
Figure 3: BDNF effects on cell survival.
Figure 4: BDNF effects in primates.

Accession codes

Accessions

Gene Expression Omnibus

Change history

  • 12 February 2009

    In the version of this article initially published online, there was an error in the heat map in Figure 2h—the description ‘BDNF:aged’ applies only to the two rightmost columns, not the three rightmost columns. Additionally, some of the P values in the legends for Figure 1a, Figure 2b,f and Figure 3b,e were incorrect. Finally, ‘entorhinal’ was misspelled in Figure 1i. The errors have been corrected for the print, PDF and HTML versions of this article.

References

  1. Gomez-Isla, T. et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 16, 4491–4500 (1996).

    CAS  Article  Google Scholar 

  2. Kordower, J.H. et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann. Neurol. 49, 202–213 (2001).

    CAS  Article  Google Scholar 

  3. Price, J.L. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 58, 1395–1402 (2001).

    CAS  Article  Google Scholar 

  4. Squire, L.R. & Kandel, E.R. Memory Chapter 5 (Scientific American Library, New York, 2000).

    Google Scholar 

  5. Yan, Q. et al. Immunocytochemical localization of TrkB in the central nervous system of the adult rat. J. Comp. Neurol. 378, 135–137 (1997).

    CAS  Article  Google Scholar 

  6. Kaplan, D.R. & Miller, F.D. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 10, 381–391 (2000).

    CAS  Article  Google Scholar 

  7. Narisawa-Saito, M., Wakabayashi, K., Tsuji, S., Takahashi, H. & Nawa, H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 7, 2925–2928 (1996).

    CAS  Article  Google Scholar 

  8. Connor, B. et al. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res. Mol. Brain Res. 49, 71–81 (1997).

    CAS  Article  Google Scholar 

  9. Hock, C., Heese, K., Hulette, C., Rosenberg, C. & Otten, U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol. 57, 846–51 (2000).

    CAS  Article  Google Scholar 

  10. Mucke, L. et al. High-level neuronal expression of aβ 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050–4058 (2000).

    CAS  Article  Google Scholar 

  11. Palop, J.J. et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. USA 100, 9572–9577 (2003).

    CAS  Article  Google Scholar 

  12. Boddaert, J. et al. Evidence of a role for lactadherin in Alzheimer's disease. Am. J. Pathol. 170, 921–929 (2007).

    CAS  Article  Google Scholar 

  13. Reddy, P.H. et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum. Mol. Genet. 13, 1225–1240 (2004).

    CAS  Article  Google Scholar 

  14. Scherzer, C.R. et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl. Acad. Sci. USA 104, 955–960 (2007).

    CAS  Article  Google Scholar 

  15. Morrison, J.H. & Hof, P.R. Life and death of neurons in the aging brain. Science 278, 412–419 (1997).

    CAS  Article  Google Scholar 

  16. Merrill, D.A., Chiba, A.A. & Tuszynski, M.H. Conservation of neuronal number and size in the entorhinal cortex of behaviorally characterized aged rats. J. Comp. Neurol. 438, 445–456 (2001).

    CAS  Article  Google Scholar 

  17. Merrill, D.A., Roberts, J.A. & Tuszynski, M.H. Conservation of neuron number and size in entorhinal cortex layers II, III and V/VI of aged primates. J. Comp. Neurol. 422, 396–401 (2000).

    CAS  Article  Google Scholar 

  18. Rowe, W.B. et al. Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic and myelinogenic pathways with cognitive impairment in aged rats. J. Neurosci. 27, 3098–3110 (2007).

    CAS  Article  Google Scholar 

  19. Holtzman, D.M. et al. TrkA expression in the CNS: evidence for the existence of several novel NGF-responsive CNS neurons. J. Neurosci. 15, 1567–1576 (1995).

    CAS  Article  Google Scholar 

  20. Peterson, D.A., Lucidi-Phillipi, C.A., Eagle, K.L. & Gage, F.H. Perforant path damage results in progressive neuronal death and somal atrophy in layer II of entorhinal cortex and functional impairment with increasing postdamage age. J. Neurosci. 14, 6872–6885 (1994).

    CAS  Article  Google Scholar 

  21. Rohn, T.T., Rissman, R.A., Head, E. & Cotman, C.W. Caspase activation in the Alzheimer's disease brain: tortuous and torturous. Drug News Perspect. 15, 549–557 (2002).

    CAS  Article  Google Scholar 

  22. Tomac, A. et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373, 335–339 (1995).

    CAS  Article  Google Scholar 

  23. Winkler, C., Sauer, H., Lee, C.S. & Bjorklund, A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16, 7206–7215 (1996).

    CAS  Article  Google Scholar 

  24. Gash, D.M. et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252–255 (1996).

    CAS  Article  Google Scholar 

  25. Kaspar, B.K., Llado, J., Sherkat, N., Rothstein, J.D. & Gage, F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839–842 (2003).

    CAS  Article  Google Scholar 

  26. Gazzaley, A.H., Thakker, M.M., Hof, P.R. & Morrison, J.H. Preserved number of entorhinal cortex layer II neurons in aged macaque monkeys. Neurobiol. Aging 18, 549–553 (1997).

    CAS  Article  Google Scholar 

  27. Taffe, M.A., Weed, M.R., Gutierrez, T., Davis, S.A. & Gold, L.H. Modeling a task that is sensitive to dementia of the Alzheimer's type: individual differences in acquisition of a visuo-spatial paired-associate learning task in rhesus monkeys. Behav. Brain Res. 149, 123–133 (2004).

    Article  Google Scholar 

  28. Gould, R.L., Brown, R.G., Owen, A.M., Fytche, D.H. & Howard, R.J. fMRI BOLD response to increasing task difficulty during successful paired associates learning. Neuroimage 20, 1006–1019 (2003).

    CAS  Article  Google Scholar 

  29. Stoop, R. & Poo, M.M. Synaptic modulation by neurotrophic factors. Prog. Brain Res. 109, 359–364 (1996).

    CAS  Article  Google Scholar 

  30. Levine, E.S., Crozier, R.A., Black, I.B. & Plummer, M.R. Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-d-aspartic acid receptor activity. Proc. Natl. Acad. Sci. USA 95, 10235–10239 (1998).

    CAS  Article  Google Scholar 

  31. Figurov, A., Pozzo-Miller, L.D., Olafsson, P., Wang, T. & Lu, B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 381, 706–709 (1996).

    CAS  Article  Google Scholar 

  32. Thoenen, H. & Sendtmer, M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat. Neurosci. 5, 1046–1050 (2002).

    CAS  Article  Google Scholar 

  33. Kordower, J.H. et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46, 419–424 (1999).

    CAS  Article  Google Scholar 

  34. Gill, S.S. et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9, 589–595 (2003).

    CAS  Article  Google Scholar 

  35. Tuszynski, M.H. et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11, 551–555 (2005).

    CAS  Article  Google Scholar 

  36. Marks, W.J., Jr. et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 7, 400–408 (2008).

    Article  Google Scholar 

  37. Kaplitt, M.G. et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369, 2097–2105 (2007).

    CAS  Article  Google Scholar 

  38. Smyth, G.K., Michaud, J. & Scott, H.S. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21, 2067–2075 (2005).

    CAS  Article  Google Scholar 

  39. Owen, A.M., Roberts, A.C., Polkey, C.E., Sahakian, B.J. & Robbins, T.W. Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 29, 993–1006 (1991).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank C. Glabe (University of California, Irvine) for Aβ1–42 peptide. We thank D. Amaral and P. Lavenex for assistance with the primate perforant path model, K. Loew, T. Mead, R. Torres and M. Mateling for technical support, and F. Gao for data analysis. This work was supported by the US National Institutes of Health (AG10435), the California Regional Primate Research Center Base Grant, the Veterans Administration, the Alzheimer's Association, the State of California (04-35530), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation and The Shiley Family Foundation.

Author information

Authors and Affiliations

Authors

Contributions

A.H.N. contributed surgery, data collection, analysis and manuscript writing for all studies; D.A.M. contributed data collection, analysis and manuscript writing for aging studies; G.C. and D.G. contributed to array studies and analysis; S.T. contributed to in vitro Aβ toxicity studies; B.E.S., G.M.S. and E.K. contributed to Aβ in vitro toxicity studies and breeding and behavior of APP mice; L.W. contributed stereology of APP mice; A.B. generated gene expression vectors; A.K. and M.V.C. contributed western blot analysis in aged rats; J.M.C. contributed ELISA and biochemical analyses; E.R. contributed surgery of APP mice; E.M. contributed synaptophysin quantification and surgery in APP mice; A.A.C. contributed surgery and behavioral analysis in aged rats and manuscript writing; M.H.T. contributed experimental design, surgery in rats and primates, data analysis and manuscript writing.

Corresponding author

Correspondence to Mark H Tuszynski.

Ethics declarations

Competing interests

M.H.T. is a scientific founder of Ceregene, Inc. and Trophin, Inc. Neither entity supported this research.

Supplementary information

Supplementary Text and Figures

Supplementary Figs. 1–4 and Supplementary Methods (PDF 647 kb)

Supplementary Data 1

Differentially expressed genes in APP-TG mice compared to WT, and effect of BDNF gene delivery (XLS 1038 kb)

Supplementary Data 2

Differentially expressed genes in aged rats compared to young, and effect of BDNF gene delivery to entorhinal cortex. (XLS 527 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nagahara, A., Merrill, D., Coppola, G. et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15, 331–337 (2009). https://doi.org/10.1038/nm.1912

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.1912

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing